J&J’s Tapentadol Raises Competitive Bar in Pain Market
Johnson & Johnson's newly approved acute pain drug tapentadol will likely face more market competition from tramadol generics than the drug the company compared it to in Phase III studies - oxycodone, analysts say
You may also be interested in...
Outlined studies include foot-surgery pain.
With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.